Physician profile
Javier E Lozano
NPI 1619949757
$1,377.48
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $157 · 2021: $228 · 2022: $127 · 2023: $206 · 2024: $60.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $265.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $444.60 | 2019-2024 | Myrbetriq, Xtandi |
| Janssen Biotech, INC. | $244.30 | 2019-2020 | |
| Amgen INC. | $167.53 | 2019-2020 | |
| Abbvie INC. | $132.56 | 2019-2024 | |
| Boston Scientific Corporation | $70.97 | 2019-2020 | |
| Calyxo, INC. | $54.86 | 2023 | Cvac Aspiration System |
| Caldera Medical, INC | $50.71 | 2023 | Desara |
| Bayer Healthcare Pharmaceuticals INC. | $48.90 | 2019-2023 | |
| Axonics, INC. | $34.91 | 2021-2023 | Axonics |
| Myovant Sciences INC. | $34.25 | 2021 | |
| Genzyme Corporation | $31.41 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $18.77 | 2020 | |
| Urovant Sciences INC | $16.81 | 2022 | |
| Palette Life Sciences, INC. | $15.48 | 2022 | |
| 180 Medical, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Lozano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.